Skip to main content

Advertisement

SpringerLink
Log in

Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease

  • Neurology and Preclinical Neurological Studies - Review Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Development of motor fluctuations and dyskinesia characterizes the transition from early to advanced Parkinson disease stage. Current therapeutic strategies to manage motor complications aim at increasing the number of levodopa administrations and extending its benefit by the association of enzyme blockers and dopamine agonists. However, as disease progresses, mobility becomes progressively dependent on levodopa absorption and its plasma bioavailability, resulting in loss of independence, worse quality of life and increased caregiver burden. If patients continue to experience off-time with functional impact on activities of daily living after best medication adjustments, implementation of infusion with apomorphine or levodopa, and surgical therapies should be considered. Presence of troublesome dyskinesia would also favor the choice of an advanced treatment. Compared with pulsatile oral therapy, both apomorphine and levodopa infusion determine more continuous striatal dopamine receptors stimulation than oral levodopa resulting in significant reduction of off-time and dyskinesia, particularly peak-dose, although not in their complete resolution. This observation proves that abnormal synaptic plasticity and connectivity changes cannot be reversed once they are established. Early implementation of these therapeutic strategies ideally would target patients as soon as motor complications begin rather than at late stage of advanced Parkinson’s disease (PD) before dyskinesia have manifested. Preliminary evidence from early deep brain stimulation in patients with short disease duration and modest motor complications suggests that this approach can positively impact quality of life. It is conceivable that changing our PD treatment algorithm and implementing device-aided therapies at the beginning of the advanced phase before dyskinesia has established, will provide more stable motor conditions and longer functional autonomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Antonini A, Tolosa E (2009) Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management. Expert Rev Neurother 9:859–867

    Article  PubMed  CAS  Google Scholar 

  • Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P (2010) Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson’s disease. CNS Drugs 24:119–129

    Article  PubMed  CAS  Google Scholar 

  • Antonini A, Isaias IU, Rodolfi G et al (2011) A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 258:579–585

    Article  PubMed  CAS  Google Scholar 

  • Antonini A, Odin P, Lopiano L et al (2013) Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care. J Neural Transm 120:1553–1558

    Article  PubMed  CAS  Google Scholar 

  • Antonini A, Fung VS, Boyd JT et al (2016) Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patients. Mov Disord 31:530–537

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Antonini A, Poewe W, Chaudhuri KR, GLORIA Study Co-investigators et al (2017) Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord 45:13–20

    Article  PubMed  Google Scholar 

  • Antonini A, Moro E, Godeiro C, Reichmann H (2018a) Medical and surgical management of advanced Parkinson’s disease. Mov Disord. https://doi.org/10.1002/mds.27340

    Article  PubMed  Google Scholar 

  • Antonini A, Robieson WZ, Bergmann L, Yegin A, Poewe W (2018b) Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson’s disease. Neurodegener Dis Manag 8:161–170

    Article  PubMed  Google Scholar 

  • Bellucci A, Antonini A, Pizzi M, Spano P (2017) The end is the beginning: Parkinson’s disease in the light of brain imaging. Front Aging Neurosci 9:330. https://doi.org/10.3389/fnagi.2017.00330

    Article  PubMed  PubMed Central  Google Scholar 

  • Bezard E (2013) Experimental reappraisal of continuous dopaminergic stimulation against l-dopa-induced dyskinesia. Mov Disord 28:1021–1022

    Article  PubMed  Google Scholar 

  • Bjornestad A, Forsaa EB, Pedersen KF, Tysnes OB, Larsen JP, Alves G (2016) Risk and course of major complications in a population-based incident Parkinson’s disease cohort. Park Relat Disord 22:48–53

    Article  Google Scholar 

  • Borgemeester RW, Drent M, van Laar T (2016) Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson’s disease patients. Park Relat Disord 23:17–22

    Article  Google Scholar 

  • Cabrera LY, Goudreau J, Sidiropoulos C (2018) Critical appraisal of the recent US FDA approval for earlier DBS intervention. Neurology. https://doi.org/10.1212/WNL.0000000000005829

    Article  PubMed  Google Scholar 

  • Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B (2010) Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol 9(11):1106–1117

    Article  PubMed  CAS  Google Scholar 

  • Carta M, Bezard E (2011) Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia. Neuroscience 198:245–251

    Article  PubMed  CAS  Google Scholar 

  • Cenci MA, Crossman AR (2018) Animal models of l-dopa-induced dyskinesia in Parkinson’s disease. Mov Disord. https://doi.org/10.1002/mds.27337

    Article  PubMed  Google Scholar 

  • Coelho M, Ferreira JJ (2012) Late-stage Parkinson disease. Nat Rev Neurol 8:435–442

    Article  PubMed  CAS  Google Scholar 

  • Dafsari HS, Reker P, Silverdale M et al (2017) Subthalamic stimulation improves quality of life of patients aged 61 years or older with short duration of Parkinson’s disease. Neuromodulation. https://doi.org/10.1111/ner.12740

    Article  PubMed  Google Scholar 

  • Drapier S, Eusebio A, Degos B et al (2016) Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study. J Neurol 263:1111–1119

    Article  PubMed  CAS  Google Scholar 

  • Elkurd MT, Bahroo LB, Pahwa R (2018) The role of extended-release amantadine for the treatment of dyskinesia in Parkinson’s disease patients. Neurodegener Dis Manag

  • Fabbri M, Coelho M, Guedes LC et al (2017) Response of non-motor symptoms to levodopa in late-stage Parkinson’s disease: results of a levodopa challenge test. Parkinsonism Relat Disord 39:37–43

    Article  PubMed  Google Scholar 

  • Fahn S, Oakes D, Shdoulson I et al (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508

    Article  PubMed  CAS  Google Scholar 

  • Fox SH, Katzenschlager R, Lim SY et al (2011) The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S2–S41

    Article  PubMed  Google Scholar 

  • Hadj Tahar A, Gregoire L, Bangassoro E, Bedard PJ (2000) Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol 23:195–202

    Article  PubMed  CAS  Google Scholar 

  • Jenner P, Katzenschlager R (2016a) Apomorphine—pharmacological properties and clinical trials in Parkinson’s disease. Parkinsonism Relat Disord 33(Suppl 1):S13–S21

    Article  PubMed  Google Scholar 

  • Jenner P, Katzenschlager R (2016b) Apomorphine—pharmacological properties and clinical trials in Parkinson’s disease. Park Relat Disord 33(Suppl 1):S13–S21

    Article  Google Scholar 

  • Katzenschlager R, Hughes A, Evans A et al (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov Disord 20:151–157

    Article  PubMed  Google Scholar 

  • Katzenschlager R, Poewe W, Rascol O et al (2018) Double-blind, randomised, placebo-controlled, phase III study (Toledo) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing ‘off’ time in Parkinson’s disease patients with motor fluctuations not well controlled on optimised medical treatment. Lancet Neurol (in press)

  • Lang AE, Rodriguez RL, Boyd JT et al (2016) Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Mov Disord 31:538–546

    Article  PubMed  CAS  Google Scholar 

  • Maratos EC, Jackson MJ, Pearce RK, Cannizzaro C, Jenner P (2003) Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than l-DOPA in the MPTP-lesioned common marmoset (Marmoset/Callithrix jacchus). Exp Neurol 179:90–102

    Article  PubMed  CAS  Google Scholar 

  • Martinez-Martin P, Reddy P, Katzenschlager R et al (2015) EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord 30:510–516

    Article  PubMed  CAS  Google Scholar 

  • Odin P, Ray Chaudhuri K, Slevin JT, National Steering Committees et al (2015) Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord 21:1133–1144

    Article  PubMed  CAS  Google Scholar 

  • Olanow CW, Kieburtz K, Odin P et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13:141–149

    Article  PubMed  CAS  Google Scholar 

  • Pilleri M, Antonini A (2015) Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease. Expert Opin Drug Saf 14:281–294

    Article  PubMed  CAS  Google Scholar 

  • Porras G, De Deurwaerdere P, Li Q, Marti M, Morgenstern R, Sohr R, Bezard E, Morari M, Meissner WG (2014) l-Dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Sci Rep 4:3730

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Schuepbach WM, Rau J, Knudsen K et al (2013) Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med 368:610–622

    Article  PubMed  CAS  Google Scholar 

  • Sensi M, Cossu G, Mancini F et al (2017) Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism Relat Disord 38:90–92

    Article  PubMed  Google Scholar 

  • Sesar Á, Fernández-Pajarín G, Ares B, Rivas MT, Castro A (2017) Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients. J Neurol 264:946–954

    Article  PubMed  CAS  Google Scholar 

  • Sharma JC, Ross IN, Rascol O, Brooks D (2008) Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol 15:493–496

    Article  PubMed  CAS  Google Scholar 

  • Stocchi F, Ruggieri S, Vacca L, Olanow CW (2002) Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain 125:2058–2066

    Article  PubMed  Google Scholar 

  • Timpka J, Fox T, Fox K, Honig H, Odin P, Martinez-Martin P, Antonini A, Chaudhuri KR (2016) Improvement of dyskinesias with l-dopa infusion in advanced Parkinson’s disease. Acta Neurol Scand 133:451–458

    Article  PubMed  CAS  Google Scholar 

  • Timpka J, Nitu B, Datieva V, Odin P, Antonini A (2017) Device-aided treatment strategies in advanced Parkinson’s disease. Int Rev Neurobiol 132:453–474

    Article  PubMed  Google Scholar 

  • Vizcarra JA, Situ-Kcomt M, Artusi CA et al (2018) Subthalamic deep brain stimulation and levodopa in Parkinson’s disease: a meta-analysis of combined effects. J Neurol. https://doi.org/10.1007/s00415-018-8936-2

    Article  PubMed  Google Scholar 

  • Wirdefeldt K, Odin P, Nyholm D (2016) Levodopa-carbidopa intestinal gel in patients with Parkinson’s disease: a systematic review. CNS Drugs 30:381–404

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuroscience, University of Padua, Via Giustiniani 3, Padua, Italy

    Angelo Antonini

  2. Colentina Clinical Hospital, Bucharest, Romania

    Bianca Nitu

Authors
  1. Angelo Antonini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bianca Nitu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelo Antonini.

Ethics declarations

Conflict of interest

Authors declare no competing interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Antonini, A., Nitu, B. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. J Neural Transm 125, 1131–1135 (2018). https://doi.org/10.1007/s00702-018-1906-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-018-1906-0

Keywords

Search

Navigation